Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmnicellMEX:OMCL 75 Debt-to-Equity is 0.15 as of Jun. 2026, which is 67% below its 10-year median of 0.45. GuruFocus rates MEX:OMCL with a GF Score™ of 75/100 and a GF Value™ of MXN779.76. The stock has 6 warning signs investors should review. Among 556 Healthcare Providers & Services companies, Omnicell ranks better than 73.56% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Omnicell's Debt-to-Equity or its related term are showing as below:
MEX:OMCL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.45 Max: 0.59
Current: 0.15
During the past 13 years, the highest Debt-to-Equity Ratio of Omnicell was 0.59. The lowest was 0.06. And the median was 0.45.
MEX:OMCL's Debt-to-Equity is ranked better than 73.56% of 556
companies
in the Healthcare Providers & Services industry
Industry Median: 0.405
vs MEX:OMCL: 0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Omnicell Debt-to-Equity Related Terms
Omnicell Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Omnicell's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:OMCL vs HTFL, TDOC, OMDA: Debt-to-Equity Comparison
For the Health Information Services subindustry, Omnicell's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Omnicell's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell (MEX:OMCL) has a Debt-to-Equity of 0.15 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Omnicell and its competitors. This is 67% below median its historical median of 0.45. Over the past decade, Omnicell's Debt-to-Equity has ranged from 0.06 to 0.59. According to the industry distribution chart, Omnicell ranks #147 out of 556 companies in the Healthcare Providers & Services industry, placing it in the top 26.4%.
Is Omnicell's Debt-to-Equity too high?
Omnicell's current Debt-to-Equity of 0.15 is 67% below median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.59. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. Omnicell's value of 0.15 is 63% below this industry median. Based on the distribution chart, Omnicell ranks #147 out of 556 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Omnicell has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's Debt-to-Equity compare to HTFL and TDOC?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #147 out of 556 companies for Debt-to-Equity. This puts Omnicell in the upper half of its industry. The industry median Debt-to-Equity is 0.41. Omnicell's value of 0.15 is 63% below this benchmark. Historically, Omnicell's own Debt-to-Equity has ranged from 0.06 to 0.59 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 0.41, Omnicell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current Debt-to-Equity of 0.15 is 63% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Omnicell and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current Debt-to-Equity is 0.15, which is 67% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (MEX:OMCL) has a current Debt-to-Equity of 0.15. The stock's GF Value™ is MXN779.76, compared to a current price of MXN761.16 — trading 2.4% below its estimated fair value. The current Debt-to-Equity is 0.15, which is 67% below median its 10-year median of 0.45 and 63% below the Healthcare Providers & Services industry median of 0.41. Omnicell's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Omnicell (MEX:OMCL), the current Debt-to-Equity is 0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (MEX:OMCL) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be undervalued.
The current stock price of MXN761.16 is trading 2.4% below its estimated GF Value™ of MXN779.76.
Key valuation signals for MEX:OMCL:
Debt-to-Equity: 0.15 (67% below median its 10-year median of 0.45)
GF Value™: MXN779.76 vs. price of MXN761.16 (2.4% below fair value)
Industry Position: 63% below the Healthcare Providers & Services median (#147 of 556)
No single metric tells the full story. See the MEX:OMCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
75GF Score
Get the complete analysis for MEX:OMCL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OMCL has been successfully added to your 
